Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  TEL AVIV STOCK EXCHANGE  >  Teva Pharmaceutical Industries Limited    TEVA   IL0006290147

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Tel Aviv Stock Exchange
04/19/2017 04/20/2017 04/23/2017 04/24/2017 04/25/2017 Date
11360(c) 11280(c) 11400(c) 11590(c) 11160(c) Last
491 097 619 449 231 515 323 913 576 167 Volume
-2.24% -0.70% +1.06% +1.67% -3.71% Change
More quotes
Financials ($)
Sales 2017 23 456 M
EBIT 2017 7 071 M
Net income 2017 4 011 M
Debt 2017 25 854 M
Yield 2017 3,78%
Sales 2018 23 190 M
EBIT 2018 7 119 M
Net income 2018 4 202 M
Debt 2018 21 087 M
Yield 2018 3,84%
P/E ratio 2017 8,07
P/E ratio 2018 7,82
EV / Sales2017 2,47x
EV / Sales2018 2,29x
Capitalization 32 039 M
More Financials
Company
Teva Pharmaceutical Industries Ltd. engages in the provision of pharmaceutical services.It operates through the following two segments: Generic and Specialty Medicine.The Generic segment includes chemical and therapeutic equivalents of originator medicines in a variety of dosage forms, including... 
Sector
Pharmaceuticals
Calendar
08/03Earnings Release
More about the company
Surperformance© ratings of Teva Pharmaceutical Indust
Trading Rating : Investor Rating :
More Ratings
Latest news on TEVA PHARMACEUTICAL INDUST
04/25 TEVA PHARMACEUTICAL INDUSTRIES : CFO Eyal Desheh to step down
04/24 TEVA PHARMACEUTICAL INDUSTRIES : launches asthma product with generic version
04/24 TEVA PHARMACEUTICAL INDUSTRIES : Releases AirDuo RespiClick plus Generic for Ast..
04/22 TEVA PHARMACEUTICAL INDUSTRIES : simultaneously launches AirDuo RespiClick and i..
04/21 TEVA PHARMACEUTICAL INDUSTRIES LTD ( : TEVA) Asthma Inhaler To Compete With Glax..
04/21 Teva's new asthma inhaler poses first competition for GSK's Advair
04/20 TEVA PHARMACEUTICAL INDUSTRIES : Patent Issued for Biomarkers Predictive for Cli..
04/20 TEVA PHARMACEUTICAL INDUSTRIES : Launches AirDuo™ RespiClick® and its Auth..
04/20 FUSION TELECOMMUNICATIONS 'L : Lombardia Capital Partners Upped its Teva Pharmac..
04/19 TEVA PHARMACEUTICAL INDUSTRIES : Showcases CNS Portfolio at 69th Annual Meeting ..
More news
Sector news : Pharmaceuticals - NEC
04/25DJSHIRE : Files 8K - Other Events
04/25DJSHIRE : Files 8K - Changes To Articles
04/25DJNasdaq Composite Tops 6000 for First Time
04/25DJASTRAZENECA : Lung Cancer Treatment Approved in EU
04/25DJELI LILLY AND : Working to Cut Costs
More sector news : Pharmaceuticals - NEC
Latest Tweets
04/25Teva Pharmaceutical Industries $TEVA Getting Favorable Press Coverage, Report.. 
04/25Teva Pharmaceutical CFO to step down: media
4
04/25[CNA] Teva Pharmaceutical CFO to step down: media  
04/25Teva Pharmaceutical: Negative In 2015, And Still Negative In 2017
1
04/25Teva Pharmaceutical CFO to step down -media  
More tweets
Qtime:32
News from SeekingAlpha
04/25 TEVA PHARMACEUTICAL : Negative In 2015, And Still Negative In 2017
04/25 Teva finance chief to depart for likely Chairmanship at consumer credit firm
04/25 APRIL BUYS : The 14 Stocks Added To My Fund
04/25 Why Teva Pharmaceuticals Has Significant Upside
04/24 My 83 Stock Portfolio Review Highlighting Defensive Sectors And My Energy Sto..
Advertisement
Chart TEVA PHARMACEUTICAL INDUST
Duration : Period :
Teva Pharmaceutical Indust Technical Analysis Chart | TEVA | IL0006290147 | 4-Traders
Full-screen chart
Technical analysis trends TEVA PHARMACEUTIC...
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Average target price 37,5 $
Spread / Average Target 18%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Yitzhak Peterburg President & Chief Executive Officer
Sol J. Barer Chairman
Carlo de Notaristefani President & CEO-Global Operations
Eyal Desheh Chief Financial Officer & Group Executive VP
Michael R. Hayden President-Global Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
TEVA PHARMACEUTICAL IN..-17.57%32 039
JOHNSON & JOHNSON6.67%333 142
ROCHE HOLDING LTD.8.21%220 797
PFIZER INC.3.88%200 926
NOVARTIS AG-1.08%195 490
MERCK & CO., INC.5.55%170 359
More Results